Cancer of the nasal cavity and paranasal sinuses.
Sinonasal malignancies continue to have poor survival rates. Disease-related mortality is usually the result of disease recurrence and progression at the primary site despite aggressive therapy. Complete surgical excision with postoperative radiation therapy remains the standard of care for resectable lesions. Improved reconstructive techniques have increased our ability to aggressively clear locally advanced disease in this anatomically challenging region, while reducing associated functional and cosmetic morbidity. Intensive multimodality treatment regimens coupled with newer medical technology may ultimately improve the long-prevailing poor prognosis of these tumors.
Maghami
Ellie
E
Memorial Sloan-Kettering Cancer Center, Head and Neck Service, 1275 York Avenue, New York, NY 10021, USA. maghamie@mskcc.org
Kraus
Dennis H
DH
D003131:Combined Modality Therapy; D006801:Humans; D009296:Nasal Cavity / Q000473:pathology*; D009669:Nose Neoplasms / Q000473:pathology* / Q000628:therapy; D010255:Paranasal Sinus Neoplasms / Q000473:pathology* / Q000628:therapy